go-v.orgdoi

Identification of novel biomarkers and therapeutic targets in Angioimmunoblastic T-cell lymphoma (AITL) mouse model

Saba Mohammaei · container not stated · 2025

  • DOI 10.82308/55804
  • Publisher OpenAlex
  • Type dissertation
  • Issued 2025

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

· OpenAlex · dissertation · 2025

Abstract

Angioimmunoblastic T-cell lymphoma (AITL), now referred to as nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (nTFHL-AI), is an aggressive subtype of peripheral T-cell lymphoma (PTCL) with poor survival rates and limited treatment options. AITL originates from neoplastic T-follicular helper (Tfh) cells, which play a crucial role in immune regulation, particularly in germinal centers. The pathogenesis of AITL involves a complex interplay of genetic mutations, including frequent alterations in the epigenetic regulators.

AITL patients exhibit significant heterogeneity in genetic mutations, contributing to challenges in understanding disease progression and developing targeted therapies. This thesis explores the mechanisms underlying AITL development, particularly focusing on the discovery of a novel malignant Tfh-like cell subset in a mouse model of AITL, Roquinsan/+ mice. These neoplastic cells, characterized by high expression of the chemokine receptor CXCR6 and the IL-18 receptor, show strong proliferative potential and drive the expansion of B cells, contributing to tumor growth.

Further investigation into these cells has revealed their dependence on the histone methyltransferase EZH2 for survival and proliferation, with deletion or pharmacological inhibition of EZH2 leading to tumor regression. This study also highlights the discovery of a distinct population of T regulatory (Treg) cells within the AITL-like tumors. These Treg cells, characterized by specific markers, appear to have a role in modulating the tumor microenvironment and influencing tumor progression, offering insights into AITL pathogenesis and treatment.

Additionally, the role of inflammatory signaling, particularly IL-18, in sustaining this malignant cell subset is highlighted, providing a potential target for therapeutic intervention. Further work is required to distinguish the role of IL-18 signaling in Tfh cells and Treg cells in AITL tumor progression. The findings presented in this work suggest that EZH2-mediated epigenetic processes, Treg cell involvement, and inflammatory signals are critical for the maintenance and progression of AITL, and targeting these pathways may offer novel therapeutic approaches for this challenging disease.

Open the resolved locator · 10.82308/55804

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 03:27 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://hdl.handle.net/20.500.14905/140989
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.